Skip to content

Author

Dylan Zuch

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jul 2026

Olezarsen and Plozasiran: Novel apoC-III targeting medications for the treatment of hypertriglyceridemia.

Overall, both olezarsen and plozasiran appear generally well tolerated, although monitoring of liver enzymes and glycemic control is warranted for both agents, and additional monitoring of platelet counts for olezarsen.

Michael S Kelly, Jelena Lewis, Dylan Zuch et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.